
July 18 (Reuters) - Sarepta Therapeutics Inc SRPT.O:
SAREPTA THERAPEUTICS SAYS 51-YEAR-OLD MALE PATIENT DIED IN AN EARLY STAGE STUDY OF CO'S THERAPY SRP-9004 - STATEMENT
SAREPTA THERAPEUTICS SAYS PATIENT WAS THE LAST TO BE DOSED IN THE STUDY, AND DIED OF ACUTE LIVER FAILURE
SAREPTA THERAPEUTICS SAYS PRIORITIZED DISCLOSING TRIAL PATIENT DEATH TO CLINICIANS, REGULATORS IN ACCORDANCE WITH TRIAL GUIDELINES
SAREPTA THERAPEUTICS SAYS ACUTE LIVER FAILURE IS NOT A NEW SAFETY SIGNAL, OCCURRED IN A TRIAL FOR A PROGRAM THAT CO IS NOT MOVING FORWARD WITH